

# UBE2T regulates FANCI monoubiquitination to promote NSCLC progression by activating EMT

JIGUANG ZHANG<sup>1,2\*</sup>, JINGDONG WANG<sup>1,2\*</sup>, JINCHENG WU<sup>1,2</sup>,  
JIANYUAN HUANG<sup>1,2</sup>, ZHAOXIAN LIN<sup>1,2</sup> and XING LIN<sup>1,2</sup>

<sup>1</sup>Shengli Clinical Medical College, Fujian Medical University; <sup>2</sup>Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China

Received October 15, 2021; Accepted May 6, 2022

DOI: 10.3892/or.2022.8350

**Abstract.** Fanconi anemia complementation group I (FANCI) is a critical protein for maintaining DNA stability. However, the exact role of FANCI in tumors remains to be elucidated. The present study aimed to explore the role and potential mechanism of action of FANCI in non-small cell lung cancer (NSCLC). To quantify the expression levels of FANCI and ubiquitin-conjugating enzyme E2T (UBE2T) in NSCLC tissues, reverse-transcription quantitative PCR and western blotting were employed. Cell Counting Kit-8, wound healing and Transwell assays along with flow cytometry analysis and tumor xenograft were used to investigate the biological effects of FANCI in NSCLC *in vitro* and *in vivo*. The binding of FANCI with UBE2T was confirmed using a co-immunoprecipitation assay. Epithelial-to-mesenchymal transition (EMT) protein markers were quantified via western blotting. The results showed that FANCI expression level was higher in NSCLC tumor tissues, compared with adjacent tissues. In

A549 and H1299 cells, knockdown of FANCI inhibited cell proliferation, migration, invasion, cell cycle and EMT *in vitro*. Tumor growth was repressed *in vitro*, upon downregulation of FANCI expression. UBE2T was observed to directly bind to FANCI and regulate its monoubiquitination. Overexpression of UBE2T reversed the effects induced by FANCI knockdown in NSCLC cells. Furthermore, it was noted that FANCI interacted with WD repeat domain 48 (WDR48). Overexpression of WDR48 reversed the effects of FANCI on cell proliferation, migration and EMT. In conclusion, FANCI was identified to be a putative oncogene in NSCLC, wherein FANCI was monoubiquitinated by UBE2T to regulate cell growth, migration and EMT through WDR48. The findings suggested that FANCI could be used as a prognostic biomarker and therapeutic target for NSCLC.

## Introduction

Lung cancer is responsible for one fifth of cancer-related deaths worldwide (1). Non-small cell lung cancer (NSCLC) is the commonest type of lung cancer (2,3). Some targeted therapies against epidermal growth factor receptor, anaplastic lymphoma kinase and c-ros oncogene 1 receptor tyrosine kinase have been confirmed to provide survival benefits to NSCLC patients. However, a considerable proportion of NSCLC remains incurable, mainly due to late diagnosis and drug resistance (4-6). Therefore, it is necessary to understand the pathogenesis of NSCLC for proper diagnosis and development of new treatment modalities. Fanconi anemia (FA) is a rare recessive disorder characterized by anemia and bone marrow failure. It is caused by mutations in the FA family proteins (7,8). The FA family consists of ~19 genes associated with cell cycle progression, regulation and DNA damage repair (9,10). FANCI is an FA family protein; its gene is located on the long arm of chromosome 15. FANCI forms a complex with its molecular chaperone FANCD2 to participate in DNA repair and ribosome biosynthesis. The complex also regulates the cell cycle in the S and G<sub>2</sub> phases (11-13). The FA core complex, which is an E3 ubiquitin ligase, monoubiquitinates FANCD2 and FANCI when DNA is damaged and stabilizes both proteins (14,15). Recently, FANCI was reported to be involved in the occurrence and development of several tumors. For example, FANCI is associated with susceptibility

---

*Correspondence to:* Dr Xing Lin, Shengli Clinical Medical College, Fujian Medical University, 134 Dong Street, Fuzhou, Fujian 350001, P.R. China  
E-mail: linxing@fjmu.edu.cn

\*Contributed equally

**Abbreviations:** CCK-8, Cell Counting Kit-8; IP, immunoprecipitation; EMT, epithelial-mesenchymal transition; FANCD2, Fanconi anemia complementation group D2; FANCI, Fanconi anemia complementation group I; FANCL, Fanconi anemia complementation group L; HBE, human bronchial epithelial; ICL, interstrand cross-link; IP, immunoprecipitation; LUAD, lung adenocarcinoma; NSCLC, non-small cell lung cancer; RT-qPCR, reverse-transcription quantitative PCR; shRNA, short hairpin RNA; UBE2T, ubiquitin-conjugating enzyme E2T; WB, western blotting; WDR48, WD repeat domain 48

**Key words:** Fanconi anemia complementation group I, non-small cell lung cancer, ubiquitin-conjugating enzyme E2T, monoubiquitination, epithelial-mesenchymal transition

to familial prostate cancer (16). It has also been used as a novel marker for hepatitis B virus-associated hepatocellular carcinoma (17). In lung adenocarcinoma (LUAD), it co-operates with inosine monophosphate dehydrogenase type II to promote tumor growth (18). However, the understanding of the role of FANCI in tumor development and progression and the corresponding mechanism involved is still very limited, especially in the case of NSCLC.

Ubiquitin-conjugating enzyme E2T (UBE2T) is an E2 ubiquitin ligase involved in the FA pathway. It binds to FANCL and facilitates the monoubiquitination of FANCD2/FANCI to promote DNA interstrand cross-link (ICL) repair (19,20). Increasing evidence demonstrates that UBE2T is involved in multiple cancers. It is reported to decrease BRCA1 expression and promote breast cancer progression (21). It has been identified as a putative biomarker of bladder cancer (22). In addition, UBE2T-mediated monoubiquitination of H2AX induces hepatocellular carcinoma radioresistance by activating checkpoint kinase 1 (23). Based on the cancer genome atlas database, UBE2T was found to be associated with a poor prognosis in NSCLC (24). It also promotes epithelial-mesenchymal transition (EMT) and accelerates NSCLC cell proliferation, migration and invasion (25). In the EMT, epithelial cells gain migratory and invasive properties, owing to the loss of apico-basal polarity and cell-cell adhesion, to become mesenchymal stem cells. EMT is closely related to tumors, depending on the biological processes of wound healing, cell migration and proliferation (26–28). Although the aforementioned studies have found that UBE2T is associated with NSCLC, the role of UBE2T in the carcinogenesis of NSCLC is yet to be explored in depth.

In the current study, FANCI was found to be overexpressed and to serve a critical role in NSCLC progression by promoting EMT. The pathogenesis mechanism involved the UBE2T-mediated stabilization and monoubiquitination of FANCI.

## Materials and methods

**Sample collection.** A total of 32 pairs of fresh NSCLC and adjacent (~5 cm) non-cancerous lung tissue samples were collected from patients (all >18 years old) who underwent surgery in Fujian Provincial Hospital between January 2015 and January 2018. The clinical information (shown in Table I) of all the patients was collected by the informed consent. This study was approved by the Medical Ethics Committee of Fujian Provincial Hospital (approval no. K2018-015-11) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

**Cell culture and transfection.** A total of five NSCLC cell lines (H1650, H1975, HCC827, A549 and H1299) and a human normal epithelial (HBE) cell line were purchased from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. RPMI-1640 (cat. no. 11875093; Thermo Fisher Scientific, Inc.) medium containing 10% fetal bovine serum (cat. no. A3160901; Gibco; Thermo Fisher Scientific, Inc.) was used to culture cells at 37°C with 5% CO<sub>2</sub> in a humidified chamber and were used for transfection when they reached 60–70% confluence. FANCI-targeting short hairpin (sh)RNA

(ATGTAAGCTCGGAGCTAATAT) and scrambled negative control (NC1 (sh-FANCI); ACGUGACACGUUGGAGAAT), sh-UBE2T (TTGTCTGGATGTTCTCAAATT) and negative control (NC2 (sh-UBE2T); UUCUCCGAACGUGUCACGUTT), as well as the pEX-UBE2T and pEX-WDR48 overexpression and the empty vectors (pEX-1) were synthesized by Shanghai GenePharma Co., Ltd. and 1 µg/µl was used for transfection with Lipofectamine® 3000 (cat. no. L3000015; Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 24 h, according to the manufacturer's protocol. Subsequent experiments were performed 24 h after transfection.

**Reverse transcription-quantitative (RT-q) PCR.** Total RNA was isolated from NSCLC tissues and cultured cells (at 80% density) using TRIzol® reagent (cat. no. 15596018; Thermo Fisher Scientific, Inc.) Nanodrop 2000 ultramicro spectrophotometer was applied for RNA purity and quantification. The cDNA Synthesis SuperMix for qPCR (cat. no. 11141ES10; Shanghai Yeasen Biotechnology Co., Ltd.) was used to synthesize cDNA according to the manufacturer's instructions. For RT-qPCR, SYBR Premix Ex Taq II (cat. no. RR420A; Takara Biotechnology Co., Ltd.) was used. RT-qPCR was conducted using a Roche Light Cycler 480 system (Roche Diagnostics, GmbH), according to the manufacturer's protocol. The following thermocycling conditions were used for qPCR: initial denaturation at 95°C for 5 min; followed by 40 cycles at 95°C for 10 sec of denaturation, 60°C for 20 sec of annealing and elongation; and 72°C for 20 sec of final extension. The 2<sup>-ΔΔC<sub>q</sub></sup> method was used to calculate the relative expression of FANCI and UBE2T (29). β-Actin served as an internal control. Primer sequences used in this study are listed in Table II.

**Western blotting (WB).** Precooled RIPA buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) was used to extract total protein from cells and tissues. The BCA Protein Assay kit (cat. no. P0012S; Beyotime Institute of Biotechnology) was used to determine protein concentrations. Proteins (60 µg per lane) were separated on 10% SDS-PAGE. Subsequently, the proteins were transferred onto polyvinylidene fluoride membranes (cat. no. 32031602; MilliporeSigma). Then, the membranes were blocked with 5% fat-free milk at room temperature for 2 h. Following blocking, the membranes were incubated with primary antibodies (1:1,000, anti-FANCI, cat. no. ab74332; 1:1,000, anti-FANCD2, cat. no. ab108928; cat. no. Abcam) 1:1,000, anti-UBE2T, cat. no. ab179802; 1:1,000, anti-WDR48, cat. no. ab230645; 1:1,000, anti-E-cadherin, cat. no. ab40772; 1:1,000, anti-N-cadherin, cat. no. ab76011; and 1:1,000, anti-Vimentin, cat. no. ab92547) purchased from Abcam at 4°C overnight, followed by incubation with corresponding secondary antibodies for 1 h at room temperature. β-actin (1:2,000, cat. no. ab8226; Abcam) was used as an internal reference protein. The membranes were visualized using ECL solution (E411-04, Vazyme Biotech Co., Ltd.). Image Lab (version 3.0; Bio-Rad Laboratories, Inc.) was used for densitometry.

**Cell proliferation.** Cell proliferation was detected using a Cell counting kit-8 (CCK-8) assay (cat. no. CK04; Dojindo Laboratories, Inc.). Cells (~4x10<sup>3</sup>) were seeded into each

Table I. Correlation of lncRNA FANCI expression with clinical variables in NSCLC patients.

Clinicopathological feature	n	FANCI expression		P-value
		High	Low	
Sex				
Male	22	10	12	0.7043
Female	10	6	4	
Age (years)				
<60	19	11	8	0.4725
≥60	13	5	8	
Tumor size (cm)				
<3	17	5	12	0.032
≥3	15	11	4	
Lymphatic metastasis				
N0	18	4	14	0.001
N1-N3	14	12	2	
Distant metastasis				
M0	17	5	12	0.032
M1	15	11	4	

NSCLC, non-small cell lung cancer; FANCI, Fanconi anemia complementation group I.

well of a 96-well plate and maintained for the indicated times. Next, 10  $\mu$ l of CCK-8 reagent was added to each well for another 2 h of incubation. Finally, the absorbance was measured at 450 nm.

**Cell migration.** Cell migration was tested using Transwell and wound healing assays. For the Transwell assay,  $\sim 5 \times 10^5$  cells, mixed in 200  $\mu$ l basal medium, were added to the upper and lower chambers of the Transwell. They were then supplemented with 500  $\mu$ l medium. After incubation for 24 h at 37°C, cells were fixed using 4% paraformaldehyde for 30 min, stained with 0.1% crystal violet for 30 min at room temperature (cat. no. C0121; Beyotime Institute of Biotechnology) and then observed under a light microscope (Olympus Corporation). For the scratch assay (wound healing assay), cells were first seeded into a 6-well plate and incubated for 24 h at 37°C using RPMI-1640 (without FBS). Then, a scratch was created with a 10  $\mu$ l pipette tip in a cell monolayer. The images were captured upon scratching and after 24 h of scratching.

**Flow cytometry.** Cell cycle and apoptosis were determined via flow cytometry using the Annexin V-FITC/PE cell apoptosis and cell cycle detection kit (cat. no. C1052; Beyotime Institute of Biotechnology) at room temperature for 30 min according to the manufacturer's protocols (30). The cell apoptosis percentage was calculated as Q2+Q4. A flow cytometer (BeamCyte; BEAMDIAG) was used for the flow cytometry. The flow cytometric data were then analyzed with CytoSYS 1.0 software (BEAMDIAG).

**Immunoprecipitation (IP).** IP was performed using the Crosslink Magnetic IP/Co-IP kit (cat. no. 88804; Thermo

Table II. Primer sequences (5'-3') for reverse-transcription quantitative PCR.

Gene	Primer sequences (5'-3')
FANCI F	CCACCTTTGGTCTATCAGCTTC
FANCI R	CAACATCCAATAGCTCGTCACC
UBE2T F	TTGATTCTGCTGGAAGGATTTG
UBE2T R	CAGTTGCCGATGTTGAGGGAT
$\beta$ -actin F	AGGGGCCGGACTCGTCATACT
$\beta$ -actin R	GGCGGCACCACCATGTACCCT

FANCI, Fanconi anemia complementation group I; UBE2T, ubiquitin-conjugating enzyme E2T; F, forward; R, reverse.

Fisher Scientific, Inc.) according to the manufacturer's instructions. Briefly, after cell lysis, 10-20  $\mu$ l of lysis solution was collected as an input for further detection. The rest of the cell lysate was treated with an anti-UBE2T antibody (cat. no. ab179802; 1:1,000; Abcam) at 4°C for 12-16 h. Then, protein A/G magnetic beads (cat. no. HY-K0202; MedChemExpress) were added to the lysate. After incubation of  $\sim 4$  h, they were collected and washed thrice to obtain the co-precipitated proteins. Subsequently, WB was conducted with anti-FANCI (1:200; cat. no. ab74332; cat. no. Abcam) and anti-FANCD2 (1:200; cat. no. ab108928; Abcam) antibodies, as aforementioned.

**Mouse tumor xenografts.** BALB/c nude mice (n=12; age, 6 weeks; female) were purchased from GemPharmatech Co. Ltd. A549/sh-NC cells or A549/sh-FANCI cells ( $\sim 5 \times 10^6$ ) were




Figure 1. FANCI expression in NSCLC tissues and cell lines. (A and B) At mRNA and protein levels, FANCI expression was higher in NSCLC tumor tissues than in adjacent tissues. (C) FANCI was remarkably overexpressed in NSCLC cell lines, compared with its expression in HBE cells. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . FANCI, Fanconi anemia complementation group I; NSCLC, non-small cell lung cancer; HBE, human bronchial epithelial.

injected into the mice in the right flanks subcutaneously ( $n=6$  per group). Tumor volume was recorded every week. The mice were sacrificed by using pentobarbital sodium (200 mg/kg) via injection into the caudal vein. Mortality was confirmed by the stopping of the heart and breathing rate (5 min), as well as the disappearance of the foot withdrawal reflex. The tumor tissues were collected for subsequent experiments. The xenograft mice in the present study survived until to sacrifice (five weeks later). Appropriate humane end points were set, including the tumor burden should be  $<10\%$  of body weight; tumors should be  $\geq 20$  mm; tumor rapid growth causing ulceration, necrosis or infection, interference with eating or ability to walk. The Animal Care and Use Committee of the Fujian Provincial Hospital (approval no. A2018-016-12) approved the *in vivo* experiments.

**Immunohistochemistry (IHC).** IHC staining was performed on paraffin-embedded mouse tissue sections. The sections were treated with primary anti-FANCI (1:1,000; cat. no. ab74332; Abcam), anti-Ki67 (1:1,000; cat. no. ab16667; Abcam) and anti-cleaved-Caspase-3 (1:1,000; cat. no. 9661; CST) antibodies overnight at  $4^{\circ}\text{C}$ . After washing with PBS, samples were incubated with corresponding secondary antibodies for 30 min at  $37^{\circ}\text{C}$  and DAPI for 10 min at room temperature. By comparing the entire tissue area at  $\times 10$  magnification, the positive staining score was defined as 0, 1, 2, 3 and 4 for 0, 1-25, 26-50, 51-75 and 76-100% staining, respectively. If the staining score was  $\geq 3$ , the protein was considered to be highly expressed.

**Statistical analysis.** The data were analyzed using GraphPad Prism 6.01 software (GraphPad, USA). The differences

between NSCLC tumor tissues and paired adjacent tissues were assessed using paired Student's *t*-test. The differences between other two groups were assessed using unpaired Student's *t*-test and differences between more than two groups were assessed using one-way ANOVA with a Tukey's post hoc test.  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

**FANCI is highly expressed in NSCLC tissues and cell lines.** Compared with the expression of FANCI in paired adjacent tissues, all 32 NSCLC tumor tissues showed higher expression of FANCI, as per results of RT-qPCR (Fig. 1A). As shown in Table I, significant correlations were found between high levels of FANCI expression and tumor size ( $P=0.032$ ), lymphatic metastasis ( $P=0.001$ ) and distant metastasis ( $P=0.032$ ). WB revealed the upregulation of FANCI in the tumors (Fig. 1B), as well as in the NSCLC cell lines (H1650, H1975, HCC827, A549 and H1299), compared with its expression in HBE cells. Among all NSCLC cell lines, A549 and H1299 cells had the highest expression of FANCI (Fig. 1C). Therefore, H1299 and A549 cells were chosen for subsequent experiments.

**Downregulation of FANCI inhibits NSCLC cell proliferation.** FANCI was knocked down in A549 and H1299 cells to evaluate its role in NSCLC. RT-qPCR showed that sh-FANCI effectively decreased FANCI expression (Fig. 2A). The results of the CCK-8 assay indicated that FANCI knockdown decreased proliferation of cancer cells, compared with the




Figure 2. Effects of *FANCI* knockdown on NSCLC cell viability. (A) *sh-FANCI* silenced the expression of *FANCI*. *FANCI* silencing (B) inhibited A549 and H1299 cell proliferation, (C) promoted cell apoptosis (as revealed by flow cytometry), (D) upregulated Bax expression and downregulated Bcl-2 expression and (E) blocked the cell cycle in A549 and H1299 cells. \* $P < 0.05$ , \*\*\* $P < 0.001$ . *FANCI*, Fanconi anemia complementation group I; NSCLC, non-small cell lung cancer; sh, short hairpin; NC, negative control.




Figure 3. Effects of *FANCI* knockdown on EMT in NSCLC cells. (A and B) Wound-healing (magnification, x10) and Transwell assays (magnification, x20) showed that downregulation of *FANCI* expression significantly inhibited cell migration and invasion in A549 and H1299 cells. (C) Knockdown of *FANCI* increased the level of EMT marker E-cadherin but reduced those of N-cadherin and vimentin. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . *FANCI*, Fanconi anemia complementation group I; EMT, epithelial-mesenchymal transition; NSCLC, non-small cell lung cancer; NS, not significant; NC, negative control.




Figure 4. Detection of UBE2T-mediated ubiquitination of FANCI. (A) IP assay showed that UBE2T could bind to FANCI in A549 and H1299 cells. UBE2T exhibited higher (B) mRNA and (C) protein levels in NSCLC tumor tissues, compared with its levels in adjacent non-cancerous tissues. (D) Transfection efficiency of *sh-UBE2T* in NSCLC cells. (E) *FANCI* mRNA level did not change significantly upon *UBE2T* silencing. (F) Downregulation of UBE2T expression reduced FANCI levels. (G) The total FANCI protein from A549 and H1299 cells was obtained using the IP method. Compared with the ubiquitin content of the control group, the enrichment of ubiquitin increased after *UBE2T* downregulation. \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . UBE2T, ubiquitin-conjugating enzyme E2T; FANCI, Fanconi anemia complementation group I; IP, immunoprecipitation; sh, short hairpin; NS, not significant; NC, negative control.

control group (Fig. 2B). Flow cytometry analysis revealed an elevated rate of apoptosis upon FANCI knockdown (Fig. 2C). The level of pro-apoptotic protein Bax increased, while that of anti-apoptotic protein Bcl-2 decreased (Fig. 2D). Furthermore, the cell cycle was blocked upon gene silencing (Fig. 2E). The above data showed that knockdown of FANCI abated cell proliferation by promoting apoptosis and cell cycle arrest in NSCLC cells.

*FANCI regulates migration and EMT in NSCLC cells.* Cell migration and invasion were attenuated, compared with those of the scrambled NC group, when FANCI expression was downregulated (Fig. 3A and B). Furthermore, to determine the

effect of FANCI on EMT, the EMT markers including cadherin (E-cadherin and N-cadherin) and vimentin were evaluated in A549 and H1299 cells. As the WB results showed, when FANCI was knocked down, the E-cadherin expression level was raised, but that of N-cadherin and vimentin was decreased (Fig. 3C), indicating FANCI could regulate the expression of cadherin. The above findings demonstrated that FANCI affects EMT in NSCLC by regulating the expression of cadherin and vimentin.

*UBE2T contributes to monoubiquitination of FANCI in NSCLC.* UBE2T induced monoubiquitination of FANCI to activate a downstream pathway. IP revealed that UBE2T bound to FANCI in A549 and H1299 cells (Fig. 4A). In NSCLC, the




Figure 5. UBE2T-mediated alleviation of the effects of *FANCI* knockdown on NSCLC cells. (A) Overexpression of UBE2T reversed the inhibitory effect of *FANCI* knockdown on cell proliferation. (B and C) Flow cytometry and WB showed that upregulation of UBE2T protected cells from the apoptosis induced by *FANCI* knockdown \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001. UBE2T, ubiquitin-conjugating enzyme E2T; FANCI, Fanconi anemia complementation group I; NSCLC, non-small cell lung cancer; sh, short hairpin; NC, negative control; NS, not significant.

mRNA and protein expression of UBE2T in tumor tissues was higher compared with that in adjacent tissues (Fig. 4B and C). sh-UBE2T-mediated knockdown of UBE2T was confirmed via RT-qPCR (Fig. 4D). Upon downregulation of UBE2T expression, FANCI mRNA level did not change significantly (Fig. 4E), but its protein level decreased (Fig. 4F), suggesting that UBE2T might regulate the stability of FANCI by binding to it. To explore the monoubiquitination of FANCI by UBE2T, co-IP was conducted and ubiquitin content was examined. The results showed that the ubiquitin content in A549/sh-UBE2T and H1299/sh-UBE2T cells was downregulated, compared with ubiquitin content in A549/NC and H1299/NC cells (Fig. 4G). By contrast, the ubiquitin content was higher in A549 and H1299/UBE2T cells than in A549 and H1299/Vector cells (Fig. 4G), indicating that UBE2T mediated monoubiquitination of FANCI in NSCLC. As FANCI is a paralog of FANCD2, the monoubiquitination of FANCD2 by UBE2T was also detected. It was found that the knockdown of *UBE2T* decreased the monoubiquitination of FANCD2, while the overexpression of UBE2T increased it (Fig. S1). However, the knockdown of FANCD2 did not have any effect on cell growth (Fig. S2).

**UBE2T mitigates the inhibitory effects of FANCI down-regulation.** To explore whether UBE2T could alleviate the effects of FANCI knockdown in NSCLC cells, UBE2T was overexpressed in *FANCI*-knockdown cells. It was found that overexpression of UBE2T promoted the proliferation of, and

repressed apoptosis in, A549 and H1299 cells when FANCI was knocked down (Fig. 5A-C). Furthermore, cell migration and invasion were also enhanced upon upregulation of UBE2T expression (Fig. 6A and B). The levels of EMT markers cadherin and vimentin were quantified using WB. Although FANCI silencing increased E-cadherin expression level and decreased N-cadherin and vimentin expression levels, the overexpression of UBE2T partly reversed this effect (Fig. 6C). The above results revealed that the functions of FANCI in NSCLC are regulated by UBE2T.

**FANCI functions via binding to WDR48.** Through *in silico* analysis (String: <https://cn.string-db.org/>), it was found that WDR48, which is related to EMT and cell growth (31), might be a downstream factor of FANCI. IP assay confirmed that FANCI could bind to WDR48 in A549 and H1299 cells (Fig. 7A). The upregulation of WDR48 reversed the inhibitory effects of FANCI silencing on cell proliferation and migration (Fig. 7B and C) and EMT. It downregulated E-cadherin expression and upregulated that of N-cadherin and vimentin (Fig. 7D). The above findings suggest that FANCI might function by binding to WDR48.

**Knockdown of FANCI inhibits tumor growth in vivo.** A549/sh-NC and A549/sh-FANCI cells were injected subcutaneously into nude mice to establish tumor xenografts. The tumor size and weight significantly reduced in




Figure 6. UBE2T-mediated alleviation of the effects of *FANCI* knockdown on EMT. (A) Wound-healing and (B) Transwell assays showed that overexpression of UBE2T reversed the *FANCI* knockdown-induced inhibition of cell invasion and migration. (C) Upregulation of E-cadherin expression and downregulation of N-cadherin and vimentin expression, caused by *FANCI* knockdown, were reversed when UBE2T was overexpressed. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . UBE2T, ubiquitin-conjugating enzyme E2T; FANCI, Fanconi anemia complementation group I; EMT, epithelial-mesenchymal transition; NC, negative control.

the sh-FANCI group, compared with the sh-NC group. The tumor volume showed a similar pattern (Fig. 8A-C). WB and IHC revealed low FANCI expression in the sh-FANCI group (Fig. 8D and E). In addition, the expression of proliferation

marker Ki67 was lower, whereas that of cleaved-caspase 3 was higher, in the sh-FANCI group (Fig. 8F and G). These data suggested that knockdown of FANCI significantly inhibited tumor growth *in vivo*.




Figure 7. Binding of FANCI to WDR48. (A) IP assay confirmed the binding of FANCI to WDR48 in A549 and H1299 cells. Upregulation of WDR48 expression relieved the inhibitory effect of *FANCI* silencing on (B) cell proliferation and (C) migration. (D) Overexpression of WDR48 reversed the upregulation of E-cadherin expression and downregulation of N-cadherin and vimentin expression, which were caused by the silencing of *FANCI* expression. \* $P < 0.05$ , \*\*\* $P < 0.001$ . FANCI, Fanconi anemia complementation group I; WDR48, WD repeat domain 48; IP, immunoprecipitation; NC, negative control; sh, short hairpin.

## Discussion

Despite remarkable efforts to treat NSCLC, such as surgery, chemotherapy, radiotherapy and targeted therapy, the 5-year overall survival rate remains unsatisfactory (32,33). Elucidating the underlying mechanisms of NSCLC tumorigenesis requires intensive and consistent exploration. An ICL refers to the covalent bond between complementary bases of double-stranded DNA, which is one of the most toxic types of DNA damage (34). The FA pathway is responsible for repairing ICLs in the S phase and maintaining genomic stability (35). FANCL, an E3 ubiquitin ligase, serves an irreplaceable role in FA pathway activation and ICL

repair. When ICLs occur on DNA, the FA core complex is recruited to the stagnated replication fork. FANCL, the E3 ubiquitin ligase subunit in the FA-core complex, interacts specifically with UBE2T and then, FANCL and UBE2T promote the monoubiquitination of the FANCI-FANCD2 heterodimer. The ubiquitinated FANCI-FANCD2 complex recruits downstream endonucleases to cut DNA. Then, the downstream proteins undergo cross-injury synthesis and homologous recombination repair to finally complete the repair of ICLs (36). FANCI was also revealed as a biomarker for the poor prognosis of LUAD (18); however, a previous study found a tumor suppressive role of FANCI, wherein it acted as a negative factor for the Akt pathway by regulating




Figure 8. Effect of *FANCI* knockdown on tumor growth *in vivo*. (A and B) Tumor weights and (C) volumes significantly decreased in the *sh-FANCI* group compared with those in the *sh-NC* group. (D) WB and (E) IHC results in tumor tissues showed that *FANCI* expression was significantly reduced in the *sh-FANCI* group. IHC revealed (F) decreased expression of Ki-67 and (G) increased expression of cleaved-caspase-3 in the *sh-FANCI* group. \* $P < 0.05$ . *FANCI*, Fanconi anemia complementation group I; sh, short hairpin; WB, western blotting; IHC, immunohistochemistry; NC, negative control.

PHLPP phosphatases (37). Therefore, the role of *FANCI* in tumors remains unclear and further studies are needed to explore it properly. The present study discovered that *FANCI* is overexpressed in NSCLC tumor tissues. Knockdown of *FANCI* inhibited EMT, proliferation, migration, invasion and tumor growth in NSCLC cells. Although *FANCI* is a paralog of *FANCD2* and *UBE2T* regulates the monoubiquitination of *FANCD2* in NSCLC cells, we found that downregulation of *FANCD2* did not influence cell growth. Based on these results, we propose that *FANCI*, but not *FANCD2*, functions as an oncogene in NSCLC. Thus, *FANCI* is a novel potential therapeutic target for NSCLC.

*UBE2T* is an E2 enzyme that is widely dysregulated in numerous cancers and functions as an oncoprotein (38,39). Recently, *UBE2T* was reported to promote  $\beta$ -catenin nuclear translocation in HCC through the MAPK/ERK axis (40). In addition, *UBE2T* promotes the progression of LUAD by regulating autophagy through the p53/AMPK/mTOR signaling pathway (41). As a member of the E2 family, *UBE2T* enhances DNA crosslinking-induced damage repair by monoubiquitinating the *FANCI-FANCD2* complex (42). Some studies have indicated that *FANCD2* is a preferred substrate for ubiquitination in the *FANCI-FANCD2* complex (15,43), but it becomes

a poor substrate for ubiquitination when *FANCI* is absent (44). Compared with *FANCD2*, free *FANCI* is more efficiently ubiquitinated by the FA-core complex (44,45). It has also been reported that the abundance of *FANCI* in U2OS cells is nearly 10 times more than that of *FANCD2*, indicating that *FANCI* may also be ubiquitinated alone in cells to a certain degree (46). The present study found that *UBE2T* expression was upregulated in NSCLC tumor tissues. Therefore, in terms of mechanism, it was hypothesized that *FANCI* might be regulated by *UBE2T* during the development and progression of NSCLC. According to the co-IP and WB assays, *UBE2T* interacted with *FANCI* and stabilized the *FANCI* level. Ubiquitin-like protein 5 (*UBL5*) has also been reported to bind *FANCI* and promote its stability (47). The present study discovered that overexpression of *UBE2T* increased the monoubiquitination level of *FANCI* in NSCLC cells. The foregoing results suggested that the function of *FANCI* in NSCLC was probably modulated by *UBE2T*-mediated monoubiquitination. However, it is still not well known how the FA-core complex and *UBE2T* specifically regulate *FANCI* monoubiquitination and this requires further research. In addition, the rescue experiments showed that overexpression of *UBE2T* partly reversed the *FANCI* knockdown-induced inhibition

of EMT, cell growth, migration and invasion, indicating that UBE2T regulates the function of FANCI in NSCLC.

WDR48 is critical for EMT. The inhibition of endogenous WDR48 expression is reported to significantly decrease TGF- $\beta$ -induced EMT, migration and invasion in tumor cells (47). The present study predicted the binding of FANCI and WDR48 using *in silico* analysis and confirmed it via IP assay. Furthermore, rescue experiments showed that the upregulation of WDR48 also reversed the FANCI knockdown-induced inhibition of EMT and cell growth. These findings indicate the probable role of WDR48 in FANCI function in NSCLC.

In conclusion, the present study revealed the oncogenic role of FANCI in promoting cell growth and EMT in NSCLC. This function of FANCI is mediated by WDR48 and regulated by UBE2T-induced monoubiquitination of FANCI. In the present study, FANCI emerged as a potential target for NSCLC therapy that may also serve as a biomarker for predicting its poor prognosis.

### Acknowledgments

Not applicable.

### Funding

The present study was funded by the National Natural Science Foundation of China (grant no. 82074189), Fujian Natural Science Foundation (grant no. 2021J01380) and Science and Technology Planning Project of Fujian Provincial Health Commission (grant no. 2021zylc31).

### Availability of data and materials

The datasets in the present study are available from the corresponding author on reasonable request.

### Authors' contributions

JZ and XL designed the study. JWa and JZ performed the experiments. XL and JW prepared the figures. JZ and XL confirm the authenticity of all the raw data. JWu, JH and ZL contributed to the drafting of the manuscript and the final approval of the version to be published. All authors read and approved the final manuscript.

### Ethics approval and consent to participate

The present study was approved by the Medical Ethics Committee of Fujian Provincial Hospital (approval no. K2018-015-11) and written informed consent was obtained from all the participants.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

1. Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. *CA Cancer J Clin* 72: 7-33, 2022.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68: 394-424, 2018.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. *CA Cancer J Clin* 66: 115-132, 2016.
4. Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G and Swanton C: Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. *Lancet* 388: 1002-1011, 2016.
5. Del Re M, Crucitta S, Gianfilippo G, Passaro A, Petrini I, Restante G, Michelucci A, Fogli S, de Marinis F, Porta C, *et al*: Understanding the mechanisms of resistance in EGFR-positive NSCLC: From tissue to liquid biopsy to guide treatment strategy. *Int J Mol Sci* 20: 3951, 2019.
6. Doval DC, Desai CJ and Sahoo TP: Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors. *Indian J Cancer* 56 (Suppl): S23-S30, 2019.
7. Kelaidi C, Makis A, Petrikos L, Antoniadis K, Selenti N, Tzotzola V, Ioannidou ED, Tsitsikas K, Kitra V, Kalpini-Mavrou A, *et al*: Bone marrow failure in Fanconi anemia: Clinical and genetic spectrum in a cohort of 20 pediatric patients. *J Pediatr Hematol Oncol* 41: 612-617, 2019.
8. Engel NW, Schliffke S, Schüller U, Frenzel C, Bokemeyer C, Kubisch C and Lessel D: Fatal myelotoxicity following palliative chemotherapy with cisplatin and gemcitabine in a patient with stage IV cholangiocarcinoma linked to post mortem diagnosis of Fanconi anemia. *Front Oncol* 9: 420, 2019.
9. Katsuki Y and Takata M: Defects in homologous recombination repair behind the human diseases: FA and HBOC. *Endocr Relat Cancer* 23: T19-T37, 2016.
10. Dong H, Nebert DW, Bruford EA, Thompson DC, Joenje H and Vasilioi V: Update of the human and mouse Fanconi anemia genes. *Hum Genomics* 9: 32, 2015.
11. Kottemann MC and Smogorzewska A: Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. *Nature* 493: 356-363, 2013.
12. Joo W, Xu G, Persky NS, Smogorzewska A, Rudge DG, Buzovetsky O, Elledge SJ and Pavletich NP: Structure of the FANCI-FANCD2 complex: Insights into the Fanconi anemia DNA repair pathway. *Science* 333: 312-316, 2011.
13. Sondalle SB, Longerich S, Ogawa LM, Sung P and Baserga SJ: Fanconi anemia protein FANCI functions in ribosome biogenesis. *Proc Natl Acad Sci USA* 116: 2561-2570, 2019.
14. Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, van de Vrugt HJ, Oostra AB, Yan Z, Ling C, Bishop CE, *et al*: A novel ubiquitin ligase is deficient in Fanconi anemia. *Nat Genet* 35: 165-170, 2003.
15. Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER III, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD and Elledge SJ: Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. *Cell* 129: 289-301, 2007.
16. Paulo P, Maia S, Pinto C, Pinto P, Monteiro A, Peixoto A and Teixeira MR: Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. *PLoS Genet* 14: e1007355, 2018.
17. Xie S, Jiang X, Zhang J, Xie S, Hua Y, Wang R and Yang Y: Identification of significant gene and pathways involved in HBV-related hepatocellular carcinoma by bioinformatics analysis. *PeerJ* 7: e7408, 2019.
18. Zheng P and Li L: FANCI cooperates with IMPDH2 to promote lung adenocarcinoma tumor growth via a MEK/ERK/MMPs pathway. *Onco Targets Ther* 13: 451-463, 2020.
19. Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D'Andrea AD and Dutta A: UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. *Mol Cell* 23: 589-596, 2006.
20. Longerich S, San Filippo J, Liu D and Sung P: FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL. *J Biol Chem* 284: 23182-23186, 2009.
21. Ueki T, Park JH, Nishidate T, Kijima K, Hirata K, Nakamura Y and Katagiri T: Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. *Cancer Res* 69: 8752-8760, 2009.

22. Zhu X, Li T, Niu X, Chen L and Ge C: Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer. *Oncol Lett* 20: 44, 2020.
23. Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, Guo Z, Liu L and Wu D: UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. *J Exp Clin Cancer Res* 39: 222, 2020.
24. Wu ZH, Zhang YJ and Sun HY: High ubiquitin conjugating enzyme E2 T mRNA expression and its prognostic significance in lung adenocarcinoma: A study based on the TCGA database. *Medicine (Baltimore)* 99: e18543, 2020.
25. Yin H, Wang X, Zhang X, Zeng Y, Xu Q, Wang W, Zhou F and Zhou Y: UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation. *Cancer Lett* 494: 121-131, 2020.
26. Hay ED: An overview of epithelio-mesenchymal transformation. *Acta Anat (Basel)* 154: 8-20, 1995.
27. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. *Curr Opin Cell Biol* 15: 740-746, 2003.
28. Zhao L, Sun H, Kong H, Chen Z, Chen B and Zhou M: The Incrna-TUG1/EZH2 axis promotes pancreatic cancer cell proliferation, migration and EMT phenotype formation through sponging Mir-382. *Cell Physiol Biochem* 42: 2145-2158, 2017.
29. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
30. Wang X, Yin H, Zhang H, Hu J, Lu H, Li C, Cao M, Yan S and Cai L: NF- $\kappa$ B-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers. *Cell Death Dis* 9: 418, 2018.
31. Han D, Wang L, Chen B, Zhao W, Liang Y, Li Y, Zhang H, Liu Y, Wang X, Chen T, *et al*: USP1-WDR48 deubiquitinase complex enhances TGF- $\beta$  induced epithelial-mesenchymal transition of TNBC cells via stabilizing TAK1. *Cell Cycle* 20: 320-331, 2021.
32. Cao J, Yuan P, Wang Y, Xu J, Yuan X, Wang Z, Lv W and Hu J: Survival rates after lobectomy, segmentectomy, and wedge resection for non-small cell lung cancer. *Ann Thorac Surg* 105: 1483-1491, 2018.
33. Gaj-Levra N, Borghetti P, Bruni A, Ciammella P, Cuccia F, Fozza A, Franceschini D, Scotti V, Vagge S and Alongi F: Current radiotherapy techniques in NSCLC: Challenges and potential solutions. *Expert Rev Anticancer Ther* 20: 387-402, 2020.
34. Rozelle AL, Cheun Y, Vilas CK, Koag MC and Lee S: DNA interstrand cross-links induced by the major oxidative adenine lesion 7,8-dihydro-8-oxoadenine. *Nat Commun* 12: 1897, 2021.
35. Yang Y, Guo T, Liu R, Ke H, Xu W, Zhao S and Qin Y: FANCL gene mutations in premature ovarian insufficiency. *Hum Mutat* 41: 1033-1041, 2020.
36. Ceccaldi R, Sarangi P and D'Andrea AD: The Fanconi anaemia pathway: New players and new functions. *Nat Rev Mol Cell Biol* 17: 337-349, 2016.
37. Zhang X, Lu X, Akhter S, Georgescu MM and Legerski RJ: FANCI is a negative regulator of Akt activation. *Cell Cycle* 15: 1134-1143, 2016.
38. Zhang W, Zhang Y, Yang Z, Liu X, Yang P, Wang J, Hu K, He X, Zhang X and Jing H: High expression of UBE2T predicts poor prognosis and survival in multiple myeloma. *Cancer Gene Ther* 26: 347-355, 2019.
39. Liu LP, Yang M, Peng QZ, Li MY, Zhang YS, Guo YH, Chen Y and Bao SY: UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. *Biochem Biophys Res Commun* 493: 20-27, 2017.
40. Lioulia E, Mokos P, Panteris E and Dafou D: UBE2T promotes  $\beta$ -catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK-dependent activation. *Mol Oncol* 16: 1694-1713, 2022.
41. Zhu J, Ao H, Liu M, Cao K and Ma J: UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma. *J Transl Med* 19: 374, 2021.
42. Nepal M, Che R, Ma C, Zhang J and Fei P: FANCD2 and DNA damage. *Int J Mol Sci* 18: 1804, 2017.
43. Sato K, Toda K, Ishiai M, Takata M and Kurumizaka H: DNA robustly stimulates FANCD2 monoubiquitylation in the complex with FANCI. *Nucleic Acids Res* 40: 4553-4561, 2012.
44. Wang S, Wang R, Peralta C, Yaseen A and Pavletich NP: Structure of the FA core ubiquitin ligase closing the ID clamp on DNA. *Nat Struct Mol Biol* 28: 300-309, 2021.
45. van Twest S, Murphy VJ, Hodson C, Tan W, Swuec P, O'Rourke JJ, Heierhorst J, Crismani W and Deans AJ: Mechanism of ubiquitination and deubiquitination in the Fanconi anemia pathway. *Mol Cell* 65: 247-259, 2017.
46. Beck M, Schmidt A, Malmstroem J, Claassen M, Ori A, Szymborska A, Herzog F, Rinner O, Ellenberg J and Aebersold R: The quantitative proteome of a human cell line. *Mol Syst Biol* 7: 549, 2011.
47. Oka Y, Bekker-Jensen S and Mailand N: Ubiquitin-like protein UBL5 promotes the functional integrity of the Fanconi anemia pathway. *EMBO J* 34: 1385-1398, 2015.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.